Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Behav Brain Res. 2011 Mar 1;217(2):399–407. doi: 10.1016/j.bbr.2010.11.018

Figure 4. SL327 had no effect on acquisition of EtOH-CPP.

Figure 4

(A) SL327 (50 mg/kg) did not prevent the development of EtOH-CPP as both groups showed significant preference for the EtOH-paired floor following acquisition (Test 1). Significant EtOH-CPP of both the Vehicle and SL-50 groups persisted across five subsequent tests for both groups. (B) When administered during CPP acquisition, SL327 (50 mg/kg) caused a general reduction in EtOH-induced activity. However, SL327 did not impair the development of EtOH-induced sensitization across the two acquisition trials. Error bars indicate standard error of the mean.

* denotes a significant increase in EtOH-induced activity from CS+-trial 1 to 2 (p < .05).

# denotes a significant difference in EtOH-induced activity between the Vehicle and SL-50 group (p < .05).